  Contribution of proteomics to colorectal cancer diagnosisMeuwis, Marie-Alice  ; Louis, Edouard ; Merville, Marie-Paule in Acta Endoscopica (2007) Detailed reference viewed: 23 (5 ULg)Pharmacogenetics of infliximab in Crohn's diseaseDideberg, Vinciane ; Louis, Edouard ; Bours, Vincent in Acta Endoscopica (2007), 37(4), 521-530 Pharmacogenetic studies will certainly contribute to a better management of medication in inflammatory bowel diseases. Infliximab is the most efficient drug in refractory and fistulising Crohn's disease ... [more ▼] Pharmacogenetic studies will certainly contribute to a better management of medication in inflammatory bowel diseases. Infliximab is the most efficient drug in refractory and fistulising Crohn's disease. However, about one third of the patients do not respond to this treatment. Several studies have been performed to identify predictive factors of the response to infliximab in CD. We attempt to summarize the current knowledge on the use of infliximab in CD and focus on the result of these studies and more particularly on pharmacogenetic aspects. [less ▲] Detailed reference viewed: 43 (1 ULg)Screening for colorectal cancer in 2006Piront, Patricia ; Louis, Edouard ; Belaiche, Jacques et alin Acta Endoscopica (2007), 37(3), 305-313 Colorectal cancer is the second leading cause of death in Northern countries and needs a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and ... [more ▼] Colorectal cancer is the second leading cause of death in Northern countries and needs a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and acceptable for patients. Many screening tools, invasive or not, are existing and often debated: FOBT, sigmoidoscopy and complete colonoscopy. New tools are in development and have to be evaluated in current practice: virtual colonoscopy, new endoscopic technologies, DNA on faeces or proteomics with markers in serum. [less ▲] Detailed reference viewed: 19 (2 ULg) Alcoholisation of a hepatocarcinoma guided by echoendoscopyGast, Pierrette ; Delwaide, Jean ; Gillard, Vincent et alin Acta Endoscopica (2006), 36(1), 74 Detailed reference viewed: 8 (1 ULg)Natural history and risk factors for colorectal cancer in inflammatory bowel diseaseLouis, Edouard ; Belaiche, Jacques in Acta Endoscopica (2004), 34 Detailed reference viewed: 15 (1 ULg)Revue de l'épidémiologie de la maladie de Crohn en EuropePiront, Patricia ; Belaiche, Jacques ; Louis, Edouard in Acta Endoscopica (2003), 33 Detailed reference viewed: 39 (2 ULg)Epidemiology, clinical presentation and diagnostic strategy of gastro-esophageal refluxLouis, Edouard in Acta Endoscopica (2003), 33 Detailed reference viewed: 26 (4 ULg) Intérêt de la tomographie à émission de positons dans l'évaluation des tumeurs gastro-intestinalesRigo, Pierre ; ; Hustinx, Roland et alin Acta Endoscopica (1999), 29(2), 129-138 La TEP au 18FDG présente de nombreuses indications dans l'évaluation des tumeurs digestives. Son rôle principal concerne le bilan d'extension des récidives tumorales démontrées ou suspectées mais des ... [more ▼] La TEP au 18FDG présente de nombreuses indications dans l'évaluation des tumeurs digestives. Son rôle principal concerne le bilan d'extension des récidives tumorales démontrées ou suspectées mais des indications plus ponctuelles concernent évalement le diagnostic différentiel des masses pancréatiques et le bilan du cancer de l'oesophage. Le principal avantage de la TEP résulte de la nature métabolique du signal indépendant et complémentaire des modifications anatomiques visibles en imagerie classique. Un autre avantage est lié à l'examen du corps entier aujourd'hui pratiqué systématiquement. La TEP trouve dès lors sa place en première ligne dans ses différentes indications. [less ▲] Detailed reference viewed: 25 (1 ULg)Maladie de Crohn. Récidives post-opératoires. Conduite à tenir.Belaiche, Jacques ; Louis, Edouard in Acta Endoscopica (1999), 29 Detailed reference viewed: 17 (1 ULg) |
||
